1. Visscher, TL & Seidell, JC (2001) The public health impact of obesity. Annu Rev Public Health 22, 355–375.
2. Allison, DB & Saunders, SE (2000) Obesity in North America. An overview. Med Clin North Am 84, 305–332.
3. Hedley, AA, Ogden, CL, Johnson, CL et al. (2004) Prevalence of overweight and obesity among US children, adolescents, and adults, 1999–2002. JAMA 291, 2847–2850.
4. Kaplan, LM (2005) Pharmacological therapies for obesity. Gastroenterol Clin North Am 34, 91–104.
5. Thearle, M & Aronne, LJ (2003) Obesity and pharmacologic therapy. Endocrinol Metab Clin North Am 32, 1005–1024.
6. Yanovski, SZ & Yanovski, JA (2002) Obesity. N Engl J Med 346, 591–602.
7. Adams, TD, Gress, RE, Smith, SC et al. (2007) Long-term mortality after gastric bypass surgery. N Engl J Med 357, 753–761.
8. Sjostrom, L, Narbro, K, Sjostrom, CD et al. (2007) Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357, 741–752.
9. Borg, CM, le Roux, CW, Ghatei, MA et al. (2006) Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg 93, 210–215.
10. le Roux, CW, Welbourn, R, Werling, M et al. (2007) Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 246, 780–785.
11. Naslund, E, Gryback, P, Hellstrom, PM et al. (1997) Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. Int J Obes Relat Metab Disord 21, 387–392.
12. National Institute for Health and Clinical Excellence (2006) Obesity Guidance on the Prevention, Identification, Assessment and Management of Overweight and Obesity in Adults and Children. NICE Clinical Guideline 43. London: NICE.
13. Dixon, AF, Dixon, JB & O'Brien, PE (2005) Laparoscopic adjustable gastric banding induces prolonged satiety: a randomized blind crossover study. J Clin Endocrinol Metab 90, 813–819.
14. Buchwald, H, Husemann, B, Leutenegger, AF et al. (1986) Morbid obesity – surgical treatment – when and how? Langenbecks Arch Chir 368, 73–79.
15. Buchwald, H (2005) Bariatric surgery for morbid obesity: health implications for patients, health professionals, and third-party payers. J Am Coll Surg 200, 593–604.
16. Maggard, MA, Shugarman, LR, Suttorp, M et al. (2005) Meta-analysis: surgical treatment of obesity. Ann Intern Med 142, 547–559.
17. Pilkington, TR, Gazet, JC, Ang, L et al. (1976) Explanations for weight loss after ileojejunal bypass in gross obesity. Br Med J 1, 1504–1505.
18. Adams, TD, Gress, RE, Smith, SC et al. (2007) Long-term mortality after gastric bypass surgery. N Engl J Med 357, 753–761.
19. Sjostrom, L, Lindroos, AK, Peltonen, M et al. (2004) Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351, 2683–2693.
20. Ojo, P, Asiyanbola, B, Valin, E et al. (2008) Post discharge prophylactic anticoagulation in gastric bypass patient – how safe? Obes Surg 18, 791–796.
21. Westling, A, Bergqvist, D, Bostrom, A et al. (2002) Incidence of deep venous thrombosis in patients undergoing obesity surgery. World J Surg 26, 470–473.
22. Encinosa, WE, Bernard, DM, Chen, CC et al. (2006) Healthcare utilization and outcomes after bariatric surgery. Med Care 44, 706–712.
23. Flum, DR, Salem, L, Elrod, JA et al. (2005) Early mortality among Medicare beneficiaries undergoing bariatric surgical procedures. JAMA 294, 1903–1908.
24. Wren, AM, Seal, LJ, Cohen, MA et al. (2001) Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86, 5992.
25. Cone, RD, Cowley, MA, Butler, AA et al. (2001) The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis. Int J Obes Relat Metab Disord 25, Suppl. 5, S63–S67.
26. Schwartz, MW, Woods, SC, Porte, D Jr et al. (2000) Central nervous system control of food intake. Nature 404, 661–671.
27. Balasubramaniam, A, Mullins, DE, Lin, S et al. (2006) Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32–36): development of an anorectic Y4 receptor selective agonist with picomolar affinity. J Med Chem 49, 2661–2665.
28. Larsen, PJ & Kristensen, P (1997) The neuropeptide Y (Y4) receptor is highly expressed in neurones of the rat dorsal vagal complex. Brain Res Mol Brain Res 48, 1–6.
29. Flier, JS (2004) Obesity wars: molecular progress confronts an expanding epidemic. Cell 116, 337–350.
30. Grill, HJ & Smith, GP (1988) Cholecystokinin decreases sucrose intake in chronic decerebrate rats. Am J Physiol 254, R853–R856.
31. Ellacott, KL, Halatchev, IG & Cone, RD (2006) Interactions between gut peptides and the central melanocortin system in the regulation of energy homeostasis. Peptides 27, 340–349.
32. Schwartz, MW, Woods, SC, Seeley, RJ et al. (2003) Is the energy homeostasis system inherently biased toward weight gain? Diabetes 52, 232–238.
33. Leibel, RL, Rosenbaum, M & Hirsch, J (1995) Changes in energy expenditure resulting from altered body weight. N Engl J Med 332, 621–628.
34. Brady, LS, Smith, MA, Gold, PW et al. (1990) Altered expression of hypothalamic neuropeptide mRNAs in food-restricted and food-deprived rats. Neuroendocrinology 52, 441–447.
35. Murakami, N, Hayashida, T, Kuroiwa, T et al. (2002) Role for central ghrelin in food intake and secretion profile of stomach ghrelin in rats. J Endocrinol 174, 283–288.
36. Wren, AM, Small, CJ, Abbott, CR et al. (2001) Ghrelin causes hyperphagia and obesity in rats. Diabetes 50, 2540–2547.
37. Nagaya, N, Moriya, J, Yasumura, Y et al. (2004) Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 110, 3674–3679.
38. Nagaya, N, Itoh, T, Murakami, S et al. (2005) Treatment of cachexia with ghrelin in patients with COPD. Chest 128, 1187–1193.
39. Neary, NM, Small, CJ, Wren, AM et al. (2004) Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89, 2832–2836.
40. Cummings, DE, Purnell, JQ, Frayo, RS et al. (2001) A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50, 1714–1719.
41. le Roux, CW, Neary, NM, Halsey, TJ et al. (2005) Ghrelin does not stimulate food intake in patients with surgical procedures involving vagotomy. J Clin Endocrinol Metab 90, 4521–4524.
42. Druce, MR, Wren, AM, Park, AJ et al. (2005) Ghrelin increases food intake in obese as well as lean subjects. Int J Obes (Lond) 29, 1130–1136.
43. Cummings, DE, Weigle, DS, Frayo, RS et al. (2002) Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346, 1623–1630.
44. English, PJ, Ghatei, MA, Malik, IA et al. (2002) Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab 87, 2984.
45. le Roux, CW, Patterson, M, Vincent, RP et al. (2005) Postprandial plasma ghrelin is suppressed proportional to meal calorie content in normal-weight but not obese subjects. J Clin Endocrinol Metab 90, 1068–1071.
46. Holst, JJ (2004) On the physiology of GIP and GLP-1. Horm Metab Res 36, 747–754.
47. Larsen, PJ, Tang-Christensen, M & Jessop, DS (1997) Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 138, 4445–4455.
48. Crawley, JN & Beinfeld, MC (1983) Rapid development of tolerance to the behavioural actions of cholecystokinin. Nature 302, 703–706.
49. Abbott, CR, Monteiro, M, Small, CJ et al. (2005) The inhibitory effects of peripheral administration of peptide YY(3–36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 1044, 127–131.
50. Feinle, C, Chapman, IM, Wishart, J et al. (2002) Plasma glucagon-like peptide-1 (GLP-1) responses to duodenal fat and glucose infusions in lean and obese men. Peptides 23, 1491–1495.
51. Fukase, N, Igarashi, M, Takahashi, H et al. (1993) Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients. Diabet Med 10, 44–49.
52. Verdich, C, Toubro, S, Buemann, B et al. (2001) The role of postprandial releases of insulin and incretin hormones in meal-induced satiety – effect of obesity and weight reduction. Int J Obes Relat Metab Disord 25, 1206–1214.
53. Edwards, CM, Todd, JF, Mahmoudi, M et al. (1999) Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9–39. Diabetes 48, 86–93.
54. Kreymann, B, Williams, G, Ghatei, MA et al. (1987) Glucagon-like peptide-1 7–36: a physiological incretin in man. Lancet ii, 1300–1304.
55. Edwards, CM, Stanley, SA, Davis, R et al. (2001) Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 281, E155–E161.
56. Gutzwiller, JP, Goke, B, Drewe, J et al. (1999) Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 44, 81–86.
57. O'Shea, D, Gunn, I, Chen, X et al. (1996) A role for central glucagon-like peptide-1 in temperature regulation. Neuroreport 7, 830–832.
58. Turton, MD, O'Shea, D, Gunn, I et al. (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379, 69–72.
59. Ruiz-Grande, C, Alarcon, C, Merida, E et al. (1992) Lipolytic action of glucagon-like peptides in isolated rat adipocytes. Peptides 13, 13–16.
60. Villanueva-Penacarrillo, ML, Marquez, L, Gonzalez, N et al. (2001) Effect of GLP-1 on lipid metabolism in human adipocytes. Horm Metab Res 33, 73–77.
61. Todd, JF, Edwards, CM, Ghatei, MA et al. (1998) Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes. Clin Sci (Lond) 95, 325–329.
62. Guerci, B & Martin, CS (2008) Exenatide: its position in the treatment of type 2 diabetes. Ann Endocrinol (Paris) 69, 201–209.
63. Soltani, N, Kumar, M, Glinka, Y et al. (2007) In vivo expression of GLP-1/IgG-Fc fusion protein enhances beta-cell mass and protects against streptozotocin-induced diabetes. Gene Ther 14, 981–988.
64. DeFronzo, RA, Ratner, RE, Han, J et al. (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28, 1092–1100.
65. Kendall, DM, Riddle, MC, Rosenstock, J et al. (2005) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28, 1083–1091.
66. Tatemoto, K & Mutt, V (1980) Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature 285, 417–418.
67. Adrian, TE, Ferri, GL, Bacarese-Hamilton, AJ et al. (1985) Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89, 1070–1077.
68. Ali-Rachedi, A, Varndell, IM, Adrian, TE et al. (1984) Peptide YY (PYY) immunoreactivity is co-stored with glucagon-related immunoreactants in endocrine cells of the gut and pancreas. Histochemistry 80, 487–491.
69. Adrian, TE, Savage, AP, Sagor, GR et al. (1985) Effect of peptide YY on gastric, pancreatic, and biliary function in humans. Gastroenterology 89, 494–499.
70. Allen, JM, Fitzpatrick, ML, Yeats, JC et al. (1984) Effects of peptide YY and neuropeptide Y on gastric emptying in man. Digestion 30, 255–262.
71. le Roux, CW, Batterham, RL, Aylwin, SJ et al. (2006) Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 147, 3–8.
72. Chelikani, PK, Haver, AC & Reidelberger, RD (2005) Intravenous infusion of peptide YY(3–36) potently inhibits food intake in rats. Endocrinology 146, 879–888.
73. Degen, L, Oesch, S, Casanova, M et al. (2005) Effect of peptide YY3–36 on food intake in humans. Gastroenterology 129, 1430–1436.
74. Koegler, FH, Enriori, PJ, Billes, SK et al. (2005) Peptide YY(3–36) inhibits morning, but not evening, food intake and decreases body weight in rhesus macaques. Diabetes 54, 3198–3204.
75. Tschop, M, Castaneda, TR, Joost, HG et al. (2004) Physiology: does gut hormone PYY3–36 decrease food intake in rodents? Nature 430, 1.
76. Boey, D, Lin, S, Karl, T et al. (2006) Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity. Diabetologia 49, 1360–1370.
77. Batterham, RL, Cowley, MA, Small, CJ et al. (2002) Gut hormone PYY(3–36) physiologically inhibits food intake. Nature 418, 650–654.
78. Acuna-Goycolea, C & van den Pol, AN (2005) Peptide YY(3–36) inhibits both anorexigenic proopiomelanocortin and orexigenic neuropeptide Y neurons: implications for hypothalamic regulation of energy homeostasis. J Neurosci 25, 10510–10519.
79. Abbott, CR, Small, CJ, Kennedy, AR et al. (2005) Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3–36) on food intake. Brain Res 1043, 139–144.
80. Batterham, RL, Cohen, MA, Ellis, SM et al. (2003) Inhibition of food intake in obese subjects by peptide YY3–36. N Engl J Med 349, 941–948.
81. White, NE, Dhillo, WS, Liu, YL et al. (2008) Co-administration of SR141716 with peptide YY3–36 or oxyntomodulin has additive effects on food intake in mice. Diabetes Obes Metab 10, 167–170.
82. Batterham, RL, Heffron, H, Kapoor, S et al. (2006) Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab 4, 223–233.
83. Greenough, A, Cole, G, Lewis, J et al. (1998) Untangling the effects of hunger, anxiety, and nausea on energy intake during intravenous cholecystokinin octapeptide (CCK-8) infusion. Physiol Behav 65, 303–310.
84. Naslund, E, King, N, Mansten, S et al. (2004) Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br J Nutr 91, 439–446.
85. Adrian, TE, Savage, AP, Bacarese-Hamilton, AJ et al. (1986) Peptide YY abnormalities in gastrointestinal diseases. Gastroenterology 90, 379–384.
86. Di Francesco, V, Zamboni, M, Dioli, A et al. (2005) Delayed postprandial gastric emptying and impaired gallbladder contraction together with elevated cholecystokinin and peptide YY serum levels sustain satiety and inhibit hunger in healthy elderly persons. J Gerontol A Biol Sci Med Sci 60, 1581–1585.
87. Baggio, LL & Drucker, DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131–2157.
88. Creutzfeldt, W, Ebert, R, Willms, B et al. (1978) Gastric inhibitory polypeptide (GIP) and insulin in obesity: increased response to stimulation and defective feedback control of serum levels. Diabetologia 14, 15–24.
89. Salera, M, Giacomoni, P, Pironi, L et al. (1982) Gastric inhibitory polypeptide release after oral glucose: relationship to glucose intolerance, diabetes mellitus, and obesity. J Clin Endocrinol Metab 55, 329–336.
90. Miyawaki, K, Yamada, Y, Ban, N et al. (2002) Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8, 738–742.
91. Ding, WG & Gromada, J (1997) Protein kinase A-dependent stimulation of exocytosis in mouse pancreatic beta-cells by glucose-dependent insulinotropic polypeptide. Diabetes 46, 615–621.
92. Borg, CM, le Roux, CW, Ghatei, MA et al. (2006) Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg 93, 210–215.
93. le Roux, CW, Aylwin, SJ, Batterham, RL et al. (2006) Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 243, 108–114.
94. Neary, NM, Small, CJ, Druce, MR et al. (2005) Peptide YY3–36 and glucagon-like peptide-17–36 inhibit food intake additively. Endocrinology 146, 5120–5127.
95. Couce, ME, Cottam, D, Esplen, J et al. (2006) Is ghrelin the culprit for weight loss after gastric bypass surgery? A negative answer. Obes Surg 16, 870–878.
96. Holdstock, C, Engstrom, BE, Ohrvall, M et al. (2003) Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans. J Clin Endocrinol Metab 88, 3177–3183.
97. Lee, H, Te, C, Koshy, S et al. (2006) Does ghrelin really matter after bariatric surgery? Surg Obes Relat Dis 2, 538–548.
98. Mancini, MC, Costa, AP, de Melo, ME et al. (2006) Effect of gastric bypass on spontaneous growth hormone and ghrelin release profiles. Obesity (Silver Spring) 14, 383–387.
99. Stenstrom, B, Zhao, CM, Tommeras, K et al. (2006) Is gastrin partially responsible for body weight reduction after gastric bypass? Eur Surg Res 38, 94–101.
100. Rubino, F & Gagner, M (2002) Weight loss and plasma ghrelin levels. N Engl J Med 347, 1379–1381.